OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, today announced that it has partnered with a leading pharmaceutical distribution company to deliver a generic erectile dysfunction (ED) drug on its patented, multilayer oral thin film (OTF), CureFilm™, into the Asian market.
CURE has reformulated a generic ED drug into an OTF strip targeted for distribution in China, Hong Kong, Japan, Korea, Singapore, the Philippines, Taiwan, Vietnam and Thailand.
“This OTF erectile dysfunction product is a testament to CURE’s ability to take generic drugs and reformulate them onto OTF products, which for this indication, offers multiple benefits including discreet administration and faster onset,” said CEO of CURE Pharmaceutical, Rob Davidson. “We are excited to be teaming up with leading distribution partners like this that will distribute our OTF ED drug throughout Asia, which is expected to see growth for ED drugs and an extremely lucrative market for generic drugs.”
The global ED drugs market is expected to reach USD 3.2 billion by 2022, according to a report by Grand View Research Inc. Specifically, the Asia Pacific market is anticipated to register positive growth from favorable patient demographics, increasing awareness of sexual diseases, and availability of affordable generic alternatives in the region.
CURE Pharmaceutical’s patented, multilayer oral thin film, CureFilm™, is designed for oral administration. Without the need for water, it delivers medications to the tongue, cheek or sublingual regions of the mouth, allowing the medication to enter the blood stream enterically, buccally or sublingually. CureFilm™ has been developed to improve upon the pharmacokinetic profile and the overall therapeutic index of an Active Pharmaceutical Ingredient (API). CureFilm™ technology enables delivery of higher doses of medications with better flavor masking.
About CURE Pharmaceutical
Cure Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, cannabinoid molecules and new chemical entities (NCEs). Cure has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. Cure has developed an array of products in cutting-edge delivery platforms. Cure is well positioned in the pharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media email@example.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling firstname.lastname@example.org P. +1646 284-9416